Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 10,856 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Communication, Message Perception, Alcohol, Cancer Prevention, Behavior, Risk
Interventions: Risk Message, Efficacy Message, Industry Deception, YAW Susceptibility, Mechanisms; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment; Procedure · Drug · Dietary Supplement + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 40 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 225
States / cities: Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler; Drug
Lead sponsor: Sunovion Respiratory Development Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 1,087 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 83
States / cities: Andalusia, Alabama • Birmingham, Alabama • Jasper, Alabama + 68 more

Conditions: Calcific Aortic Valve Disease
Interventions: Evogliptin, Placebo; Drug
Lead sponsor: REDNVIA Co., Ltd.; Industry
Eligibility: 35 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 21 more

Conditions: Multiple Sclerosis
Interventions: Ponesimod, Placebo; Drug · Other
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 26
States / cities: Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Stichting European Myeloma Network; Network
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 27
States / cities: Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, Selonsertib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions: Carboplatin, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy, Paclitaxel; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 14
States / cities: Orange, California • Hartford, Connecticut • New Britain, Connecticut + 9 more

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: Sorafenib, stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 41
States / cities: Berkeley, California • Los Angeles, California • San Francisco, California + 32 more

Conditions: Moderate Clostridium Difficile Infection
Interventions: LFF571, Vancomycin (POC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 14
States / cities: Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more

Conditions: Postherpetic Neuralgia
Interventions: Z160, Placebo; Drug
Lead sponsor: Zalicus; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more

Conditions: Suicide, Attempted, Suicidal Ideation
Interventions: Crisis Response Planning for Suicide Risk; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions: temozolomide, capecitabine; Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 323
States / cities: Anaheim, California • Antioch, California • Baldwin Park, California + 221 more

Conditions: Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma, Solar Radiation-related Skin Melanoma, Stage IV Melanoma, Superficial Spreading Malignant Melanoma
Interventions: gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 178
States / cities: Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, Lispro Low Mix, Lispro Mid Mix, Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 30 Years to 79 Years
Enrollment: 2,091 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 138
States / cities: Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more

Conditions: Relapsing Multiple Scelrosis
Interventions: Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 59
States / cities: Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more

Conditions: Resistant Hypertension, Hypercortisolism
Interventions: Not listed
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1,143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 50
States / cities: Huntington Park, California • La Jolla, California • Los Angeles, California + 42 more

Conditions: Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma, HCC
Interventions: Mogamulizumab + Nivolumab; Biological
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Gilbert, Arizona • Greenbrae, California • Los Angeles, California + 12 more

Conditions: Crohn Disease
Interventions: GED-0301, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 136
States / cities: Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more

Conditions: Tobacco Smoking
Interventions: Cigarettes, E-Cigarette, Nicotine Gum or Lozenge; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Buffalo, New York • Columbus, Ohio

Conditions: Plaque Psoriasis
Interventions: Placebo, ABT-874; Drug · Biological
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 1,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 93
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 76 more

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Cigarette Smoking, Nicotine Oral Pouch, Questionnaire Administration; Behavioral · Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: GERD
Interventions: Endoflip 2.0, High Resolution Manometry; Device · Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Postoperative Complications
Interventions: Phone Call; Other
Lead sponsor: Syed Husain; Other
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Messages That Motivate: Communicating Alcohol-Related Breast Cancer Risk to Young Adult Women

Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma

A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD

A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Selonsertib in Adults With Pulmonary Arterial Hypertension

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

Assessing the Effectiveness of Self- and Clinician-administered Crisis Response Planning for Suicide Risk

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Methods Project 4: Clinical Trial - Amended

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population

Endoscopic Esophageal Topography (Endoflip 2.0) Versus High-resolution Manometry (HRM)

Evaluation of Hospital Readmission Rate Dependent on Post-Operative Follow-Up Procedure